#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Renal disorder Wiskott-Aldrich syndrome Prophylaxis against transplant rejection Non-renal cell carcinoma of kidney Oropharyngeal squamous cell carcinoma Wolfram syndrome Loss of consciousness Chronic myelomonocytic leukaemia Astrocytoma Spinal cord injury cervical Pelizaeus-Merzbacher disease Pancreatic neuroendocrine tumour Von Willebrand's disease Synovial sarcoma Isodicentric chromosome 15 syndrome More trials…

    Learn about Rare Diseases

    Behcet’s syndrome – Life with Disease Osteosarcoma metastatic – Life with Disease Epidermolysis bullosa – Diagnostics Osteosarcoma recurrent – Trials in Disease Cholangitis sclerosing – Treatment Prader-Willi syndrome Mantle cell lymphoma refractory – Treatment Hereditary optic atrophy Usher’s syndrome – Life with Disease Waldenstrom’s macroglobulinaemia – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tolu Balsam Rct2100 Taxanes TIFCEMALIMAB Mocravimod Maraviroc Capsaicin GOVORESTAT Sebetralstat Filgrastim Calcium Chloride Dihydrate RNK001 Bi-1808 BENZYLPENICILLIN PROCAINE Infliximab Metolazone Cipaglucosidase Alfa [18F]CPFPX Vibegron Azithromycin More therapies…

    Learn about Your Condition

    Glanzmann's disease Colorectal cancer stage IV Leiomyosarcoma Ichthyosis Infection Malignant melanoma stage IV Anal abscess Lymphocytic leukaemia Hyponatraemia Hypotension Liposarcoma recurrent Colorectal cancer stage II Peritoneal abscess Subarachnoid haemorrhage K-ras gene mutation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Hospitalier Universitaire Rouen

Centre Hospitalier Universitaire Rouen

1 Rue De Germont, Rouen, 76000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of fampridine treatment for patients with spinocerebellar ataxia SCA27B caused by FGF14 gene mutation

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Fampridine
    France

  • Study of inhaled interferon beta-1a (SNG001) for treatment of patients with viral lower respiratory tract infections who require mechanical ventilation

    Not recruiting

    2 1
    Investigated Drugs:
    • Interferon Beta-1A
    Belgium France The Netherlands Spain

  • Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Small cell lung cancer extensive stage
    Investigated Drugs:
    • Siltuximab
    • Carboplatin
    • Durvalumab
    Austria Belgium Denmark France Germany Greece +7

  • Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Zolbetuximab
    • Capecitabine
    • Fluorouracil
    Belgium Czechia France Germany Italy Lithuania +5

  • Study of FOLFIRI with Domvanalimab and Zimberelimab in patients with advanced gastric or gastro-esophageal junction cancer who progressed after chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastric cancer
    Investigated Drugs:
    • Domvanalimab
    • Zimberelimab
    • Fluorouracil
    France

  • Study of cisplatin, gemcitabine and rilvegostomig treatment in patients with high-risk resectable intrahepatic cholangiocarcinoma

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Cholangiocarcinoma
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine
    • Rilvegostomig
    France

  • Study of baxdrostat compared to placebo to treat adults with primary aldosteronism

    Not recruiting

    3 1
    Investigated Diseases:
    • Primary hyperaldosteronism
    Investigated Drugs:
    • Baxdrostat
    France Germany Italy Spain

  • Study of ruxolitinib cream applied to the skin for people with hidradenitis suppurativa

    Not recruiting

    3 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Ruxolitinib
    Belgium Bulgaria France Germany The Netherlands Poland +1

  • Effectiveness and Safety of Rezafungin in Adults with Chronic Pulmonary Aspergillosis Who Have Limited Treatment Options

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Bronchopulmonary aspergillosis
    Investigated Drugs:
    • Rezafungin Acetate
    Austria Belgium France Germany Hungary Italy +2

  • Study of microglial activation and synaptic density using [18F]-DPA-714, [18F]-Ro948, [11C]-UCB-J, and [11C]PiB PET imaging in patients with Alzheimer’s disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • (4R)-1-[(3-(11C)Methylpyridin-4-Yl)Methyl]-4-(3,4,5-Trifluorophenyl)Pyrrolidin-2-One
    • (N-METHYL-(11C))2-(4′-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE
    • 2-(6-[18F]Fluoro-Pyridin-3-Yl)-9H-Dipyrido[2,3-B:3′,4′-D]Pyrrole
    France
Previous Page
1 … 27 28 29 30 31 … 48
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!